Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 2
2005 2
2006 3
2007 1
2008 4
2009 4
2010 2
2011 2
2012 2
2013 7
2014 7
2015 4
2016 6
2017 1
2018 3
2019 3
2020 3
2021 3
2022 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Adjustment for continuous confounders: an example of how to prevent residual confounding.
Groenwold RH, Klungel OH, Altman DG, van der Graaf Y, Hoes AW, Moons KG; PROTECT WP2 (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium, Work Programme 2 [Framework for pharmacoepidemiology studies]). Groenwold RH, et al. CMAJ. 2013 Mar 19;185(5):401-6. doi: 10.1503/cmaj.120592. Epub 2013 Feb 11. CMAJ. 2013. PMID: 23401401 Free PMC article. Review. No abstract available.
Inpatient drug utilization in Europe: nationwide data sources and a review of publications on a selected group of medicines (PROTECT project).
Sabaté M, Ferrer P, Ballarín E, Rottenkolber M, Amelio J, Schmiedl S, Reynolds R, Klungel O, Ibáñez L; PROTECT Work Package 2. Sabaté M, et al. Basic Clin Pharmacol Toxicol. 2015 Mar;116(3):201-11. doi: 10.1111/bcpt.12358. Epub 2014 Dec 29. Basic Clin Pharmacol Toxicol. 2015. PMID: 25420967 Free article. Review.
Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: a study of inhaled long-acting beta2-agonist use and the risk of myocardial infarction.
Uddin MJ, Groenwold RH, de Boer A, Afonso AS, Primatesta P, Becker C, Belitser SV, Hoes AW, Roes KC, Klungel OH. Uddin MJ, et al. Among authors: belitser sv. Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1:132-41. doi: 10.1002/pds.3860. Pharmacoepidemiol Drug Saf. 2016. PMID: 27038359
Efficacy gap between phase II and subsequent phase III studies in oncology.
Vreman RA, Belitser SV, Mota ATM, Hövels AM, Goettsch WG, Roes KCB, Leufkens HGM, Mantel-Teeuwisse AK. Vreman RA, et al. Among authors: belitser sv. Br J Clin Pharmacol. 2020 Jul;86(7):1306-1313. doi: 10.1111/bcp.14237. Epub 2020 Feb 21. Br J Clin Pharmacol. 2020. PMID: 32034790 Free PMC article. Clinical Trial.
Instrumental variables: application and limitations.
Martens EP, Pestman WR, de Boer A, Belitser SV, Klungel OH. Martens EP, et al. Among authors: belitser sv. Epidemiology. 2006 May;17(3):260-7. doi: 10.1097/01.ede.0000215160.88317.cb. Epidemiology. 2006. PMID: 16617274
Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.
Tavenier AH, Hermanides RS, Ottervanger JP, Tolsma R, van Beurden A, Slingerland RJ, Ter Horst PGJ, Gosselink ATM, Dambrink JE, van Leeuwen MAH, Roolvink V, Kedhi E, Klungel OH, Belitser SV, Angiolillo DJ, Pustjens T, Rasoul S, Gho B, Stein M, Ruiters L, van 't Hof AWJ. Tavenier AH, et al. Among authors: belitser sv. Eur Heart J Cardiovasc Pharmacother. 2022 Jan 5;8(1):4-12. doi: 10.1093/ehjcvp/pvaa095. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 32730628 Free PMC article. Clinical Trial.
57 results